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Objectives. To investigate potential subgroups of primary care diagnosed patients with polymyalgia 
rheumatica (PMR) based on self-reported pain and stiffness severity over time. 
Methods. 652 people with an incident PMR diagnosis were recruited from English general practices 
and completed a baseline postal questionnaire. They were followed-up with a further six 
questionnaires over a two-year period. 446 people completed 2-year follow-up. Pain and stiffness 
were reported on 0-10 numerical rating scales. Latent class growth analysis was used to estimate the 
joint trajectories of pain and stiffness over time. A combination of statistical and clinical considerations 
was used to choose the number of clusters. Characteristics of the classes were described. 
Results. Five clusters were identified. One cluster represented the profile of ‘classical’ PMR symptoms 
and one represented sustained symptoms that may not be PMR. The other three clusters displayed a 
partial recovery, a recovery followed by worsening and a slow, but sustained recovery. Those 
displaying classical PMR symptoms were in better overall health at diagnosis than the other groups.  
Conclusions. PMR is a heterogeneous condition, with a number of phenotypes.  The spectrum of 
presentation, as well as varying responses to treatment, may be related to underlying health status at 
diagnosis. Future research should seek to stratify patients at diagnosis to identify those likely to have 
a poor recovery and in need of an alternative treatment pathway. Clinicians should be aware of the 
different experiences of patients and monitor symptoms closely, even where there is initial 
improvement.  
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Key messages 
 Pain and stiffness in polymyalgia rheumatica may be more variable across individuals than 
previously thought 
 Distinct groups of individuals with different symptom experiences over time have been 
identified 





Polymyalgia rheumatica (PMR), a relatively common inflammatory rheumatological condition, is 
under-researched, especially in primary care where the majority of patients are exclusively diagnosed 
and managed.[1,2] PMR causes disabling pain and stiffness in the shoulder and hip girdles, often 
accompanied by raised inflammatory markers (e.g. erythrocyte sedimentation rate (ESR), C-reactive 
protein (CRP)), but can present atypically or with non-specific symptoms, especially in the early stages. 
The mainstay of treatment is with oral glucocorticoids, which typically, although not always [3] bring 
about rapid relief of symptoms and improve physical function. Guidelines suggest a gradual tapering 
of glucocorticoid treatment over 18 to 24 months,[4] although recent evidence suggests that 
treatment is often required for longer,[5,6] which may increase the likelihood of experiencing 
potentially serious treatment-related adverse effects. 
 
To date, the majority of PMR research has been conducted in secondary care settings, which given 
guidance on indications for referral for specialist review,[7] potentially induces spectrum bias (i.e. 
study samples including patients with atypical presentation and/or more severe/difficult to treat 
disease). We therefore have little knowledge of the course of PMR in relation to its symptoms or 
treatment in the setting in which it is most frequently diagnosed and managed.  
 
In order to provide an evidence-base to understand the wider epidemiology of PMR, the PMR Cohort 
study was established in 2012.[8,9] To our knowledge, this inception cohort of patients with PMR, 
recruited in England at the time of diagnosis, is the only prospective large-scale study of incident PMR 
in a primary care setting. A key aim of this cohort, supported by patient groups, [10] is to better 
understand the prognosis of the condition. This may identify subgroups of patients who do not 
respond to glucocorticoids as expected, or who are otherwise suitable for early interventions.  
 
In this paper, we use latent class growth models [11] in data from the PMR Cohort Study to derive 
clinically recognisable groups of patients with differing patterns of pain and stiffness over two years. 
We consider whether the presentation of a patient at the time of diagnosis is different in those who 




Study procedures and the baseline sample have been described in detail elsewhere.[8,9] Briefly, 




practitioner (GP) between June 2012 and June 2014. No study-specific diagnostic criteria were applied 
and participants were considered to have PMR if their assessing general practitioner considered this 
to be their diagnosis and entered an associated Read code (primary care clinical coding system used 
in the UK) into their medical record. Participating GPs were also provided with a copy of the British 
Society for Rheumatology guidelines on the diagnosis of PMR to support making an accurate diagnosis 
[7]. Potential participants were mailed a baseline questionnaire. On return of the baseline 
questionnaire and consent to participate, participants received follow-up questionnaires 1, 4, 8, 12, 
18 and 24 months after their initial diagnosis unless they explicitly withdrew consent or lost capacity 
to continue (e.g. death, additional comorbidities).  
 
Patient and Public Involvement 
The original idea for this study came from discussion with patients. Patients were involved in the 
design of data collection materials.  
 
Data collection 
PMR-related pain and stiffness were reported on a 0-10 numerical rating scale (NRS) in each 
questionnaire. Participants also reported duration of morning stiffness and their current prednisolone 
dose. Physical functioning was assessed using the Modified Health Assessment Questionnaire 
(mHAQ)[12,13] on which normal functioning is considered to be a score of 0.33 or below. General 
health was assessed using the EQ-5D[14]; fatigue using the FACIT-Fatigue[15]; insomnia the Insomnia 
Severity Index[16]; anxiety the Generalised Anxiety Disorders-7[17]; and depression using the Patient 
Health Questionnaire-8[18]. At each time point, participants were asked to shade in blank body 
manikins to indicate where they had pain and stiffness (separately). A transparent overlay was used 
to record areas of the body where pain/stiffness were reported. This method is widely used and has 
previously been shown to be reliable.[19] 
 
Statistical analysis 
Responders and non-responders to the 1-month and 24-month questionnaires were compared on 
their sociodemographic, general health and PMR-specific characteristics at baseline using appropriate 
summary statistics. Similarly, the characteristics of the cohort over the seven time points were 







Latent Class Growth Analysis (LCGA)  
Latent class growth analysis (LCGA) is a data driven approach used to estimate the trajectory of a 
construct over time.[11] Rather than seeking to describe relationships among variables, LCGA 
identifies clusters of individuals within the dataset. In this case, LCGA was used to estimate the joint 
trajectories of pain and stiffness, as previous work has shown that patients consider them to be 
interlinked.[20]  Due to the shape of average trajectories of pain and stiffness (Supplementary Figure 
S1), which could not be well-represented by a polynomial curve, piecewise linear polynomial LCGA 
models were fitted to the data with a breakpoint at 1 month (time scale for analysis is months); i.e. 
separate polynomials were fitted between baseline and 1-month and between 1- and 24-months’ 
follow-up. Models were fitted using MPlus Version 8.2 to ascertain the number of longitudinal clusters 
present.[21] Models were fitted to all available data, assuming data were missing at random. 
Parameters were estimated via maximum likelihood with robust standard errors, due to the non-
Normal distribution of responses. Each model was run with 5000 randomly generated starting values 
with 500 iterations in order to ensure the highest log-likelihood value was replicated. 
 
Statistical and clinical considerations were taken into account when deciding on the number of 
clusters. Having assigned individuals to the cluster to which they had the highest probably of 
belonging, descriptive statistics were used to describe the characteristics of the clusters resulting from 
the LCGA model. Additional analyses were conducted in Stata 15.2.[22] 
 
Sensitivity analyses 
To test the robustness of our findings and missing data assumptions in terms of the shape of the 
identified trajectories, analyses were repeated, 1) in complete data, as in previous studies;[23] and 2) 
restricting the sample to those aged 50 years or over at diagnosis, who reported morning stiffness 
duration to be ≥45 minutes at baseline, had bilateral pain and/or stiffness in the shoulders and were 
prescribed oral glucocorticoids at the time of diagnosis. This set of criteria was agreed by an 
independent group of rheumatologists to be clinically suggestive of PMR. In these analyses, we 
assumed that the appropriate number of clusters was the same as in the main analysis (for 
completeness, fitting models with up to 7 clusters is shown in the Supplementary materials) in order 
to compare the stability and shapes of the pain-stiffness trajectories over this number of clusters in 





This study complies with the Declaration of Helsinki. Ethical approval for this study was received from 
the Staffordshire Research Ethics Committee (REC reference number: 12/WM/0021) and all patient 
provided written informed consent. 
 
RESULTS 
Cohort recruitment and retention 
Of those who were referred into the study by their GP (n=739), 652 completed the baseline 
questionnaire and entered the cohort (adjusted response rate 90.1%). 446 (77.8%) completed the 24-
month questionnaire (Figure 1). Younger age, female gender, lower occupational class, higher levels 
of pain, anxiety, depression and fatigue, and poorer general health and physical functioning at 
baseline were associated with lower rates of subsequent response (Table 1). 
 
PMR and general health characteristics of the sample over time 
As previously reported,[8] the median levels of pain and stiffness at diagnosis were eight out of ten 
(Table 2). For both symptoms, this fell to two out of ten after the first month and remained low on 
average over the rest of the follow-up period, but varied greatly at the individual level (Supplementary 
Figure S2). Similarly, 71% of people (n=452) reported morning stiffness of more than one hour at 
diagnosis, which fell to 26% at 1-month and remained at this level. Levels of physical functioning and 
fatigue also improved from diagnosis to 1-month before remaining stable. The proportion of people 
reporting anxiety, depression and insomnia decreased throughout the period of the study. General 
health, as measured by the EQ-5D remained stable throughout, as did self-reported BMI.  
 
Pain and stiffness trajectories 
All LCGA models converged. The model fit statistics (Akaike Information Criterion, Bayesian 
Information Criterion, Sample-size adjusted BIC and parametric bootstrapped likelihood ratio test) 
suggested that six or more clusters would be the best fit, whilst the Vuong-Lo-Mendell-Rubin 
likelihood ratio test and Lo-Mendell-Rubin likelihood ratio test suggested only four clusters (Table 3). 
Considering the plots of pain and stiffness for four clusters, this model was deemed to be 
uninformative (Supplementary Figure S3), as the trajectories were parallel and did not appear clinically 
meaningful. A model with six clusters was considered too complex. A five cluster model was therefore 
deemed most appropriate (Figure 2). This choice of model is broadly supported by the entropy 
statistic, cluster sizes and the average posterior probability of cluster membership. Clusters in this 




characteristics of the clusters at baseline). Variability of individual trajectories within each cluster can 
be seen in Supplementary Figure S4. 
 
Characteristics of individuals within the identified clusters 
 Baseline characteristics varied across the five clusters (Table 4). In general, those assigned to Cluster 
4 (rapid and sustained recovery) were in better health at baseline (considering scores on the EQ5D 
and mHAQ, levels of depression, anxiety, fatigue, insomnia and BMI), and were more likely to be male. 
Those assigned to Cluster 1 (sustained symptoms) were likely to be in poorer health and were less 
likely to be prescribed glucocorticoids.  
Over the course of the study, the proportion of people prescribed glucocorticoids decreased in all 
clusters. The dose of prednisolone was similar across clusters in the first year, but after 12-months 
follow-up, the median dose was noticeably higher in Cluster 1 than in other clusters (Supplementary 
Table S1). 
At the 2-year follow-up, 21% of people reported having been referred to a specialist for their PMR. 




360 people had complete data for both the pain and stiffness score at all seven time points. Missing 
data were due to a combination of non-response to the questionnaire and failure to complete the 
individual items. The LCGA model converged and a five cluster solution was assumed, as described 
above. Full details of the model fitting process are presented in Supplementary Figure S5 and 
Supplementary Table S3. Supplementary Figures S6 and S7 show the final fitted trajectories and the 
individual variability within these, respectively. In those included in this analysis, 92% (n=330) were 
allocated to the same cluster as in the original model (Supplementary Table S4). All of those with 
severe and sustained symptoms remained in this group and 95% of those with rapid and sustained 
recovery (classical PMR presentation) remained in this group. The major difference in the shape of 
pain and stiffness trajectories was in the sustained symptoms cluster, which appeared to have more 
of a reduction in symptoms followed by an increase than in the original model.   
 
PMR definition 
453 (70%) met the stricter definition of PMR (Supplementary Data S1). 24 people did not meet these 
criteria because they had not completed the items relating to either morning stiffness or 




morning stiffness (n=128 (20%)). The LCGA model converged and assuming a 5 cluster solution. Full 
details of the model fitting process are presented in Supplementary Figure S8 and Supplementary 
Table S5. The final fitted trajectories and the variability within them are shown in Supplementary 
Figures S9 and S10 respectively.  Approximately 88% (n=398) of people remained in the same cluster 
as in the original model. Where individuals moved between clusters, it tended to be between the 
clusters with poorer prognosis (Supplementary Table S6). Over 98% of those originally classified as 
having rapid and sustained recovery (classical PMR presentation) remained in this group. Over half of 
the sustained symptoms cluster from the original model were excluded from this sensitivity analysis. 
The shape of the pain and stiffness trajectories for the sustained symptoms group was slightly 
different in this sample compared to the full sample: the median pain score at baseline was higher 
than in the full sample, before reducing to a lower level at 1-month and increasing again more rapidly 




This is the first large scale study of PMR patients in primary care and reveals that there are multiple 
symptom trajectories. PMR, as diagnosed in primary care, appears to be a heterogeneous condition 
with patterns of symptom trajectories differing across patient groups. There is a group in which 
symptoms mirror the pattern of rapid and sustained recovery described in the literature. However, 
the majority of people report more varied and less straightforward symptom patterns.  
 
Restricting the sample to those meeting criteria agreed by rheumatologists to be clinically suggestive 
of PMR excluded around one third of the sample. The effect of these exclusions on the analysis was 
informative. Similar distinct groups were identified, however the group with sustained symptoms was 
disproportionately affected. More than half of this group were excluded and the shape of the 
symptom trajectory also changed. A more substantial improvement in initial symptoms followed by a 
more extreme increase suggests that this group may not have had PMR, but other conditions that 
were temporarily improved slightly by glucocorticoid treatment. Given the difficulty in making an 
accurate diagnosis of PMR [24] this scenario may not be uncommon and suggests that comorbidity 
may play a significant role in the accuracy of the diagnostic process and/or the symptom experience.  
 
Comparison of our cohort to current research literature 
Starting dose of glucocorticoid was similar in this cohort to that described in a recent American study 




that treatment with glucocorticoids in PMR lasts considerably longer than suggested by current 
guidelines.[4] and echoes some of the latest findings from large primary care database studies.[6] 
 
The causes of this longer glucocorticoid treatment require further study. Possible explanations include 
higher initial glucocorticoid dose, more severe baseline symptoms (e.g. levels of disability, 
inflammatory markers) and comorbidities. Shbeeb et al [5] found no association between initial dose 
and time to permanent discontinuation of treatment, but did find an association between initial dose 
and time to maintaining doses below 10mg/day and 5mg/day. Our finding that median dose over time 
was higher in clusters with persistent pain and stiffness suggest that doctors may be maintaining 
higher doses to treat continuing symptoms, rather than to ensure symptoms do not reoccur.  
 
Strengths and weaknesses 
The major strength of this study in comparison to previous studies of PMR, is its recruitment from 
primary care, as less than 20% of patients with PMR ever see a rheumatology specialist,[1] and only a 
subset of these will be referred at the time of diagnosis. By recruiting from general practices 
throughout England, we have included those who were diagnosed in both primary and secondary care 
settings, as specialists will refer patients back to primary care, where we would still have identified 
them for inclusion into the study. We were therefore able to avoid the spectrum bias potentially seen 
in studies recruiting exclusively from specialist settings. We ensured a high response rate at each 
follow-up point by keeping questionnaires short and using a reminder system for non-responders. 
 
Whilst the LCGA models can be estimated in the presence of missing data, we cannot be sure that 
data are missing at random, particularly as participants in poorer health at baseline were less likely to 
respond at follow-up. We chose to model pain and stiffness together in a dual trajectory model due 
to the similarity in the shape of the trajectories; we thereby included more information. This is in 
keeping with qualitative data that suggest that stiffness is intertwined with pain and also with 
function.[20] The same study also described a lack of consensus among patients regarding the best 
way to measure stiffness with some considering the numerical rating scale chosen in our study to be 
appropriate and others preferring to relate stiffness to function. It could be argued that the 0-10 scale 
is a crude measure and may experience floor or ceiling effects. However, we do not consider there to 
be true floor and ceiling effects in this study, as participants were asked to consider 0 “no pain” and 
10 “pain as bad as can be”. Therefore, scores of 0 and 10 should not be seen to ‘truncate’ the 






Due to our recruitment strategy, we were reliant on the GP to accurately diagnose PMR and to ensure 
this we provided all participating practices with a copy of the most recent British Society for 
Rheumatology guidelines on the diagnosis of PMR.[7] To improve diagnostic accuracy further, we 
constructed a set of criteria based on clinical symptoms considered suggestive of PMR. Whilst the 
clusters derived from our LCGA were similar after applying these criteria, around 30% of people did 
not meet them. This may reflect inaccurate diagnosis in primary care, but may also reflect a difference 
in opinion between primary and secondary care on what constitutes PMR especially in the context of 
multi-morbidity. However, as we do not have data related to other morbidities, we were unable to 
relate the different pain and stiffness trajectories to the presence of other comorbidities (e.g. 
osteoarthritis, giant cell arteritis (GCA)), or medications. The potential co-occurrence of GCA is a 
particular point to consider, as people with PMR are known to also have GCA in up to 20% of cases 
[25]. Whilst it is unlikely that the presence of GCA has a dramatic effect on the reporting of pain and 
stiffness from PMR it may influence glucocorticoid doses and hence symptom reporting.   
 
Implications for research and practice 
We have successfully identified a group of people with a classical PMR presentation, where current 
treatment guidelines appear to be appropriate. However, we have also identified a group that may 
not have PMR and may require more robust diagnostic processes, potentially involving additional 
investigations, periods of close monitoring or early specialist referral for diagnostic clarification or 
alternative interventions. The logical next steps for research should be to develop processes to identify 
these two groups at an early stage. Attention should then be paid to those remaining, who display 
some response to glucocorticoid treatment, but do not maintain a full reduction in symptoms in the 
long-term. Further studies need to address whether use of adjunctive treatments (e.g. exercise) are 
of benefit. Future research should therefore consider how best to stratify patients at initial diagnosis 
to identify those with potential differential diagnoses or a need for a different treatment pathway 
(e.g. adjunctive physiotherapy, rheumatology management).  
 
In the meantime, clinicians, especially those in primary care, should be aware of the potential for PMR 
to be a more heterogeneous condition than the literature suggests. In particular, they should consider 
alternative diagnoses in those who do not respond as expected to glucocorticoids in the first month 
and be aware of the potential for the return of symptoms or inability to taper their treatment 






It is unclear whether PMR is a single condition with multiple phenotypes, or a group of conditions. It 
is unlikely that all of the heterogeneity seen in primary care is attributable to diagnostic inaccuracy. 
The spectrum of presentation, as well as varying responses to treatment, are made all the more 
difficult with the high level of multimorbidity in this group. The complex interaction of comorbidities 
and polypharmacy on the presentation and subsequent response to treatment is largely unknown in 
PMR but may be critical in our understanding of the condition. Future work should aim to delineate 
these sub-conditions early in the disease course in order that patients can receive appropriate 
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Table 1  Patient Characteristics and Attrition at 1 and 24 months according to baseline characteristics 








Age (years) (Mean (SD)) 72.5 (9.3) 70.6 (9.0) 72.9 (8.7) 71.3 (10.3) 











IMD rank (Median (IQR))1 20228 (12849, 25248) 17978 (10045, 25443) 204114 (13566, 25395) 17870 (9376, 25136) 
Occupational class (n (%))     
 Higher managerial, admin & 
professional 
Intermediate 
























































Pain (0-10 NRS) (Median (IQR)) 8 (7, 9) 8 (7, 10) 8 (7, 9) 8 (7, 10) 
Stiffness (0-10 NRS) (Median (IQR)) 8 (7, 9) 8 (6, 10) 8 (7, 9) 8 (6, 9) 
Morning stiffness duration (n (%))     














































mHAQ score (Median (IQR)) 0.375 (0, 0.875) 0.75 (0.25, 1.25) 0.375 (0, 0.875) 0.5 (0.125 (1.094) 
EQ5D score (Median (IQR)) 0.73 (0.59, 0.85) 0.62, (0.415, 0.69) 0.76 (0.62, 0.88) 0.675 (0.52, 0.8) 
FACIT-Fatigue (Mean (SD)) 34.3 (12.4) 29.8 (11.3) 3.4 (11.7) 30.5 (13.1) 
ISI score (n (%))     
No clinically significant/subthreshold 
insomnia 









Effect on intimate and sexual relationships (n (%))    
 Not relevant 330 (56.0) 31 (63.3) 238 (54.3) 123 (61.5) 
 Little effect 154 (26.2) 10 (20.4) 127 (29.0) 37 (18.5) 
 Large effect 105 (17.8) 8 (16.3) 73 (16.7) 40 (20.0) 





Table 2: Cohort characteristics over time 
Baseline characteristic Baseline  Month 1  Month 4  Month 8  Month 12  Month 18  Month 24  
Pain (0-10 NRS) (Median (IQR)) 8 (7,9) 2  (1, 4) 2  (1, 4) 3 (1, 5) 2 (1, 4) 2 (1, 5) 2 (0, 5) 
Stiffness (0-10 NRS) (Median (IQR)) 8 (7,9) 2 (1, 5) 3 (1, 5) 3 (1, 5) 3 (1, 5) 3 (1, 5) 3 (1, 5) 
Morning stiffness >60 minutes (n (%)) 452 (71.1) 155 (26.4) 152 (26.4) 152 (27.7) 131 (27.0) 118 (26.0) 117 (27.0) 
Report taking prednisolone (n (%)) 625 (97.1) 564 (94.6) 518 (93.8) 463 (88.2) 397 (80.5) 323 (69.2) 255 (58.4) 
Prednisolone dose (mg) (Mean (SD)) 15.6 (7.4) 12.2 (6.6) 8.6 (5.1) 6.4 (4.1) 5.6 (3.8) 5.2 (4.2) 4.8 (3.4) 
EQ5D score (Median (IQR)) 0.73 (0.59, 0.85) NA NA NA 0.73 (0.62, 0.81) NA 0.73 (0.62, 0.81) 
mHAQ score (Median (IQR)) 0.402 (0, 1) 0.25 (0, 0.63) 0.25 (0, 0.75) 0.25 (0, 0.75) 0.25 (0, 0.71) 0.25 (0, 0.75) 0.25 (0, 0.75) 
FACIT-Fatigue score (Mean (SD)) 33.9 (12.3) 36.3 (12.2) NA NA 36.4 (11.2) NA 36.8 (11.4) 
Clinically relevant insomnia (n (%)) 145 (23.6) 103 (17.7) NA NA 61 (12.8) NA 56 (13.1) 
Moderate/severe depression1 (n (%)) 131 (21.8) 85 (15.2) NA NA 58 (12.5) NA 50 (12.4) 
Moderate/severe anxiety2 (n (%)) 79 (13.0) 79 (13.7) NA NA 47 (10.0) NA 36 (8.6) 
BMI (Mean (SD)) 27.7 (5.4) NA NA NA 27.9 (5.1) NA 27.5 (5.0) 
1Measured on PHQ8; 2Measured on GAD7; BMI restricted to values between 10 and 100kg/m2; IQR – interquartile range; SD – standard deviation; n- 




Table 3: Latent Class Growth Analysis (LCGA) – piecewise model selection (n=650)a 




PB LRT Cluster sizes Average posterior probability of 
cluster membership 
1 34148 34237 34174 N/A N/A N/A N/A 650 1.00 
2 31586 31707 31621 0.865 P<0.0001 P<0.0001 P<0.0001 229, 421 0.90, 0.99 
3 30867 31019 30911 0.827 P=0.003 P=0.003 P<0.001 129, 257, 264 0.90, 0.90, 0.94 
4 30605 30789 30659 0.808 P=0.038 P=0.041 P<0.001 146, 219, 234, 51 0.84, 0.91, 0.89, 0.87 
5 30339 30554 30402 0.788 P=0.063 P=0.067 P<0.001 52, 157, 106, 224, 111 0.87, 0.88, 0.78, 0.93, 0.75 
6 30185 30431 30257 0.793 P=0.124 P=0.129 P<0.001 30, 117, 138, 106, 210, 49 0.71, 0.83, 0.82, 0.79, 0.92, 0.87 
7 30086 30363 30166 0.786 P=0.414 P=0.418 P<0.0001 208, 27, 130, 82, 109, 45, 49 0.94, 0.86, 0.79, 0.76, 0.85, 0.78, 0.68 
AIC – Akaike Information Criterion; BIC – Bayesian Information Criterion; ABIC – Sample-size adjusted BIC; VLMR LRT – Vuong-Lo-Mendell-Rubin likelihood 
ratio test; LMR LRT – Lo-Mendell-Rubin likelihood ratio test; PBLRT – parametric bootstrapped likelihood ratio test; p – p-value. 
Model choice: choose model with lowest AIC, BIC, ABIC; entropy>0.8. Significant p-value for VLMR LRT, adjusted LMR LRT and PB LRT (suggests model over 
model with one fewer clusters). Number in each cluster should be >5% of sample size (i.e.>32). Average posterior probability of cluster membership should 
be >0.7  




Table 4: Baseline characteristics of cohort by cluster (n=650) 
Baseline characteristic Cluster 1 (n=52) Cluster 2 (n=157) Cluster 3 (n=106) Cluster 4 (n=224) Cluster 5 (n=111) 
Cluster description Sustained 
symptoms 




Rapid and sustained 
recovery 
Slow and continuous 
recovery 
Age (Mean (SD)) 71.0 (10.0) 71.4 (10.5) 72.6 (9.0) 72.9 (8.0) 73.1 (9.5) 
Female (n (%)) 38 (73.1) 113 (72.0) 63 (59.4) 117 (52.2) 74 (66.7) 
Pain (0-10 NRS) (Median 
(IQR)) 
8 (6.75, 10) 9 (7, 10) 8 (7, 9.25) 8 (6, 8) 8 (7, 10) 
Stiffness (0-10 NRS) (Median 
(IQR)) 
8 (6, 9) 8 (7, 10) 8 (7, 9) 8 (6, 8) 8 (7, 10) 
Morning stiffness >60 
minutes (n (%)) 
33 (66.0) 114 (77.6) 78 (77.2) 148 (67.6) 78 (71.6) 
Report taking prednisolone (n 
(%)) 
44 (86.3) 149 (96.1) 104 (98.1) 219 (98.7) 108 (100.0) 
Prednisolone dose (mg) 
(Median (IQR)) 
15 (15, 20) 15 (12.5, 20) 15 (12, 20) 15 (12.5, 20) 15 (10, 20) 
EQ5D score (Median (IQR)) 0.52 (0.19, 0.69) 0.66 (0.52, 0.76) 0.80 (0.70, 1.0) 0.80 (0.71, 1.0) 0.69 (0.62, 0.80) 
mHAQ score (Median (IQR)) 1.00 (0.50, 1.25) 0.63 (0.38, 1.13) 0.38 (0.00, 0.75) 0.13 (0.00, 0.50) 0.50 (0.25, 1.00) 
FACIT-Fatigue score (Mean 
(SD)) 
23.2 (12.1) 30.0 (12.1) 36.1 (10.7) 39.0 (11.1) 32.3 (11.4) 
Clinically relevant insomnia (n 
(%)) 
28 (58.3) 43 (28.7) 17 (17.0) 33 (15.8) 24 (22.9) 
Moderate/severe depression 
(n (%)) 
17 (38.6) 29 (20.0) 10 (10.3) 10 (4.7) 13 (11.9) 
Moderate/severe anxiety (n 
(%)) 
26 (56.5) 41 (28.3) 17 (17.7) 19 (9.2) 28 (26.2) 
BMI (Mean (SD)) 28.4 (6.0) 29.3 (6.1) 27.5 (5.2) 26.9 (4.8) 26.9 (4.5) 
SD – standard deviation; NRS – numerical rating scale; IQR – interquartile range; n – number; mg – milligrams; EQ5D – EuroQoL (measure of quality of life); 





























Figure 2: Fitted latent growth curves of pain and stiffness in 5 cluster model (n=650) 
 
